Comparative Pharmacology
Head-to-head clinical analysis: CIPRO versus CIPRO XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO versus CIPRO XR.
CIPRO vs CIPRO XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription, leading to bacterial cell death.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription.
Ciprofloxacin 500 mg PO q12h or 400 mg IV q12h for uncomplicated infections; 750 mg PO q12h or 400 mg IV q8h for severe/complicated infections.
500 mg to 1000 mg orally once daily for 7 to 14 days; extended-release tablet must be swallowed whole and administered with food.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours (normal renal function), extended to 8-10 hours in mild-to-moderate renal impairment (CrCl 30-50 mL/min) and up to >10 hours in severe impairment (CrCl <30 mL/min); half-life in elderly may be 5-8 hours due to reduced clearance.
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, allowing twice-daily dosing; due to extended-release formulation, ciprofloxacin is released over 24 hours.
Renal (50-70% unchanged via glomerular filtration and tubular secretion); biliary/fecal (15-20%, primarily as metabolites); small amount metabolized to 4 metabolites (oxo-, sulfo-, and desethylene-ciprofloxacin).
Renal excretion of unchanged drug accounts for approximately 40-50% of the dose; hepatic metabolism (glucuronidation, sulfation) produces active metabolites, and biliary/fecal elimination (via feces) accounts for 20-35% of the dose.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic